A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Treprostinil palmitil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Insmed
Most Recent Events
- 10 Jun 2025 Primary endpoint (Change from Baseline in Pulmonary Vascular Resistance at Week 16) has been met.
- 10 Jun 2025 Results presented in the Insmed Media Release
- 08 May 2025 According to an Insmed media release, topline data expected in June 2025.